[{"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-001", "question": "A 45-year-old woman with a 1.7-cm left adrenal incidentaloma has mild hypertension and intermittent headaches. She is on a thiazide diuretic. Labs show: K 3.3 mmol/L, plasma aldosterone 15 ng/dL, plasma renin activity 0.1 ng/mL/h (suppressed), and aldosterone-renin ratio (ARR) of 150 (elevated). Confirmatory saline suppression test is borderline. Adrenal vein sampling (AVS) without cosyntropin stimulation reveals: cortisol-corrected aldosterone lateralization index (LI) of 2.2, but contralateral suppression index <0.3. Which is the most appropriate next step in management?", "options": ["Left laparoscopic adrenalectomy, given imaging-concordant unilateral lesion and contralateral suppression", "Continue medical therapy with mineralocorticoid receptor antagonists because lateralization index is below traditional cutoff", "Repeat AVS with cosyntropin stimulation to clarify lateralization before deciding on surgery", "Proceed to partial (cortical-sparing) resection of the left adrenal nodule to preserve adrenal function", "Observation without intervention, as results suggest nonfunctioning incidentaloma"], "answer": "A", "answer_index": 0, "explanation": "Current AVS interpretation emphasizes both lateralization and contralateral suppression; a low contralateral aldosterone/cortisol ratio (<0.3) strongly indicates unilateral disease even with modest LI, especially with concordant imaging and biochemical primary aldosteronism. Medical therapy (B) or observation (E) ignores resectable unilateral disease. Repeating AVS (C) is unnecessary given clear suppression. Partial adrenalectomy (D) is not standard for unilateral aldosterone-producing adenomas and risks recurrence.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "target_topic", "source_label_raw": "Endocrine", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed130.jsonl", "pred": "A", "model_outputs": "The patient has biochemical evidence of primary aldosteronism (low potassium, elevated aldosterone, suppressed renin, high ARR) with a left adrenal nodule.  \nAVS without cosyntropin stimulation shows a cortisol-corrected aldosterone lateralization index (LI) of 2.2, which is borderline (traditional cutoff often ≥2–4 depending on protocol), but importantly there is contralateral suppression (contralateral suppression index <0.3), which strongly supports unilateral disease.  \nContralateral suppression is a key criterion in some guidelines to confirm unilateral disease even if LI is modest.  \nGiven the concordant imaging and contralateral suppression, surgery is indicated.  \n\nOption A is correct because AVS shows contralateral suppression, confirming unilateral hypersecretion, and the nodule is on the same side.  \n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-002", "question": "A 63-year-old man with compensated cirrhosis (Child-Pugh A, MELD 9) has a 2.3-cm hepatocellular carcinoma (HCC) in segment VII adjacent to the right hepatic vein and diaphragm. He has portal hypertension with platelets 70,000/µL, small varices, and HVPG 13 mmHg. Liver function is preserved; he is not yet listed for transplant due to social issues. Which management offers the best balance of long-term oncologic control and hepatic reserve preservation?", "options": ["Open right posterior sectionectomy including segment VII and part of VIII", "Laparoscopic wedge resection of segment VII tumor with Pringle maneuver", "Ultrasound-guided percutaneous radiofrequency ablation (RFA) of the lesion", "Transarterial chemoembolization (TACE) followed by reassessment for ablation or resection", "Listing for liver transplantation without locoregional therapy until a donor becomes available"], "answer": "C", "answer_index": 2, "explanation": "For a solitary ≤3-cm HCC in a cirrhotic liver with significant portal hypertension and thrombocytopenia, percutaneous ablation achieves local control comparable to resection with lower risk of hepatic decompensation. Major or even limited resection (A, B) carries high risk in portal hypertension (HVPG >10 mmHg). TACE (D) is inferior to curative-intent ablation for small lesions. Delayed transplant without bridging (E) risks progression beyond criteria and prevents near-term curative local control.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed130.jsonl", "pred": "C", "model_outputs": "The patient has a single small HCC (2.3 cm) in a challenging location (adjacent to diaphragm and right hepatic vein), with preserved liver function but significant portal hypertension (HVPG >10 mmHg, thrombocytopenia, varices).  \n\n- **A (Open right posterior sectionectomy)** – Major resection; higher morbidity and mortality risk given portal hypertension, and overkill for a 2.3 cm tumor.  \n- **B (Laparoscopic wedge resection)** – Possible, but location near major vein and diaphragm makes laparoscopic wedge resection with clear margins difficult; still carries surgical risk with portal hypertension.  \n- **C (Percutaneous RFA)** – For tumors ≤3 cm, RFA is often first-line with curative intent, especially in high surgical risk patients. However, subdiaphragmatic location near hepatic vein may cause heat-sink effect or risk incomplete ablation.  \n- **D (TACE then reassessment)** – Usually for larger or multifocal HCC; not first-line curative for a single small HCC when ablation/resection possible.  \n- **E (Listing without bridge therapy)** – Not appropriate because tumor may progress while waiting; transplant not yet arranged due to social issues.  \n\nGiven portal hypertension (surgical resection risk increased) and tumor size ≤3 cm, current guidelines favor thermal ablation (RFA) as first-line for patients not optimal for resection. Percutaneous RFA offers good oncologic control, minimal impact on hepatic reserve, and is less invasive. Despite the challenging location, it is still considered the best balance here.  \n\nThe answer is C"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-003", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "source_question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T045001943Z_gpt-5.1-2025-11-13_seed123.jsonl", "pred": "B", "model_outputs": "This patient has severe pulmonary arterial hypertension (PAH) confirmed by right heart catheterization (pre-capillary, PVR ≥3 Wood units, PCWP ≤15 mmHg).  \nThe clues:  \n- High PVR and mPAP  \n- Normal V/Q scan rules out CTEPH  \n- Positive family history suggests possible heritable PAH (e.g., BMPR2 mutation).  \n- Acute vasoreactivity testing showed partial response (mPAP drop ≥10 mmHg to 42 mmHg, but not to ≤40 mmHg with normal CO), so she is not a “responder” by traditional criteria (not eligible for high-dose calcium channel blocker therapy).  \n\nCurrent guidelines for severe PAH (FC likely III–IV given CI 2.1) recommend initial combination therapy (ambrisentan + tadalafil) to reduce risk of clinical worsening, supported by the AMBITION trial.  \n\nMonotherapy with riociguat or intravenous epoprostenol is not first-line for this scenario over initial oral combo in a non-responder; IV epoprostenol is for high-risk or FC IV not improving. Warfarin target INR 3.0–4.0 is not standard in PAH without other indications.  \n\nThus, the best evidence-based choice for initial long-term therapy is ambrisentan + tadalafil.  \n\nThe answer is B"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-004", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "topics_mapped", "source_label_raw": "Nephrology", "source_quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "source_question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T045001943Z_gpt-5.1-2025-11-13_seed127.jsonl", "pred": "B", "model_outputs": "The patient has type 2 diabetes with CKD stage 3b (eGFR 37) and persistent albuminuria (ACR 620 mg/g), indicating high cardiorenal risk.  \nHe is already on lisinopril (ACEi), empagliflozin (SGLT2 inhibitor), and high-intensity statin — foundational therapies for cardiorenal protection.  \n\n- **A**: Increasing empagliflozin dose is not proven to add significant cardiorenal benefit beyond the standard dose (10 mg daily is effective even with reduced eGFR).  \n- **B**: Adding finerenone (a nonsteroidal MRA) is indicated in this setting based on trials (FIDELIO, FIGARO) showing reduced cardiorenal events in patients with T2D, CKD, and albuminuria already on ACEi/ARB and SGLT2 inhibitors, provided potassium is acceptable (K+ 4.6, no hyperkalemia history).  \n- **C**: Switching to sacubitril/valsartan could be considered, but evidence in non–heart failure CKD patients is less robust than for finerenone in this specific T2D + albuminuria population, and BP is already low (118/66).  \n- **D**: Tightening glycemic control with basal insulin to A1c <6.5% is not recommended for reducing cardiorenal risk in this high-risk patient and may increase hypoglycemia risk.  \n- **E**: Adding a non-DHP CCB is for BP/angina control, not specific cardiorenal risk reduction here.  \n\nThe most appropriate evidence-based addition is finerenone with monitoring of potassium.  \n\nThe answer is B"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-005", "question": "A 26-year-old man presents with splenomegaly, hemoglobin 9.8 g/dL, platelets 130,000/µL, and leukocytes 5,200/µL. Peripheral smear shows tear-drop cells and leukoerythroblastosis. Bone marrow biopsy is markedly fibrotic with 1-2% blasts; JAK2, CALR, and MPL mutations are negative; next-generation sequencing reveals an isolated ASXL1 mutation. Cytogenetics are normal. He is transfusion independent but symptomatic from splenomegaly. DIPSS-plus score indicates intermediate-2 risk primary myelofibrosis. His 10/10 HLA-matched sibling donor is available. Which is the most appropriate management strategy?", "options": ["Begin ruxolitinib and defer allogeneic stem cell transplantation until he becomes transfusion dependent", "Proceed to allogeneic stem cell transplantation in first chronic phase despite triple-negative driver status", "Observation with serial monitoring; ASXL1 mutation alone does not justify early transplant", "Splenectomy followed by hydroxyurea cytoreduction to delay transplantation", "Ruxolitinib bridge therapy for 3-6 months to reduce spleen size, then proceed to planned allogeneic transplantation"], "answer": "E", "answer_index": 4, "explanation": "Intermediate-2 risk myelofibrosis in a young patient with an available donor warrants allogeneic transplant; bridging with ruxolitinib can reduce spleen size and improve conditioning tolerance without compromising transplant timing. Deferring transplant (A, C) risks disease progression. Splenectomy (D) before transplant is reserved for select cases due to morbidity. Immediate transplant without JAK inhibitor optimization (B) may lead to worse peri-transplant outcomes in massively enlarged spleens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed130.jsonl", "pred": "E", "model_outputs": "For a young patient with intermediate-2 risk primary myelofibrosis, symptomatic splenomegaly, and an available matched sibling donor, allogeneic stem cell transplantation is the preferred curative option. Ruxolitinib bridge therapy is commonly used to reduce spleen size and alleviate symptoms before transplantation, potentially improving transplant outcomes. This approach balances symptom management with timely definitive treatment.\n\nThe answer is E"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-006", "question": "A 31-year-old woman with systemic lupus erythematosus, class IV lupus nephritis, and high-titer anti-dsDNA presents with a 4-week history of progressive symmetric lower extremity weakness, areflexia, and sensory loss. NCS/EMG show a demyelinating polyneuropathy consistent with CIDP. She is on prednisone 10 mg daily and hydroxychloroquine. Creatinine is 1.3 mg/dL; she has nephrotic-range proteinuria. Which immunologic treatment strategy best balances disease control and long-term toxicity?", "options": ["High-dose IV methylprednisolone pulses followed by oral prednisone 1 mg/kg for both CIDP and lupus nephritis", "IVIG monthly for CIDP plus increase prednisone to 0.5 mg/kg, with no other agents", "Rituximab-based regimen targeting both CIDP and lupus nephritis with tapering of steroids", "Cyclophosphamide induction followed by azathioprine maintenance for lupus and CIDP", "Plasma exchange for CIDP plus mycophenolate mofetil for lupus nephritis"], "answer": "C", "answer_index": 2, "explanation": "Rituximab has efficacy in both CIDP (especially autoimmune-mediated forms) and proliferative lupus nephritis, allowing steroid sparing and addressing shared B-cell pathogenesis. High-dose steroids alone (A, B) worsen long-term toxicity and may be insufficient for nephritis. Cyclophosphamide (D) carries more gonadal and malignancy risk in a young woman. Plasmapheresis (E) gives transient CIDP benefit but does not control chronic B-cell-driven lupus nephritis as effectively as rituximab-based regimens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed130.jsonl", "pred": "C", "model_outputs": "The patient has two immune-mediated conditions: active class IV lupus nephritis (with nephrotic-range proteinuria) and CIDP.  \nBoth require effective immunosuppression, but long-term steroid toxicity is a concern.  \n\n- **A** uses high-dose steroids only, which would not be steroid-sparing and carries high long-term toxicity.  \n- **B** uses IVIG (good for CIDP) and moderate-dose prednisone increase, but inadequate for class IV lupus nephritis.  \n- **C** (rituximab) can treat both CIDP and lupus nephritis, allows steroid tapering, and avoids alkylating agents.  \n- **D** (cyclophosphamide) is effective for lupus nephritis but less established for CIDP and has higher gonadal/oncogenic risks.  \n- **E** uses plasma exchange (temporary) plus mycophenolate (good for lupus nephritis), but mycophenolate is not first-line for CIDP.  \n\nRituximab is a reasonable biologic option for refractory SLE and CIDP, offering steroid-sparing benefit and avoiding cyclophosphamide toxicity.  \n\nThe answer is C"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-007", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "source_question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T045001943Z_gpt-5.1-2025-11-13_seed123.jsonl", "pred": "C", "model_outputs": "The presentation is consistent with dermatomyositis (Gottron papules, mechanic's hands, proximal muscle weakness) complicated by interstitial lung disease (ILD). The ILD pattern on CT and pulmonary function tests suggests significant involvement, and the key is identifying the antibody most associated with rapidly progressive ILD in this context.\n\n- **Anti-MDA5** is strongly associated with dermatomyositis, especially with rapidly progressive ILD, poor prognosis, and often minimal muscle involvement (can have normal or only mildly elevated CK). The dry cough, ground-glass opacities, traction bronchiectasis, and markedly reduced DLCO fit this pattern.\n\n- **Anti-Jo-1** is linked to antisynthetase syndrome and ILD, but progression is often subacute rather than rapidly progressive.\n\n- **Anti-Mi-2** is associated with classic dermatomyositis but lower risk of ILD.\n\n- **Anti-SRP** is linked to severe necrotizing myopathy but not typically with rapidly progressive ILD.\n\n- **Anti-TIF1-γ** is associated with malignancy in dermatomyositis, not rapidly progressive ILD.\n\nThus, anti-MDA5 indicates the highest risk of rapidly progressive ILD needing early aggressive immunosuppression.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-008", "question": "A 42-year-old man who injects drugs presents with 10 days of fever, severe back pain, and new right leg weakness. Vitals: T 38.8°C, HR 108, BP 122/74. Exam: midline lumbar tenderness, right leg 3/5 strength with hyperreflexia, left leg 5/5, intact sensation, no bowel/bladder symptoms. Labs: WBC 15,000/µL, ESR 96 mm/hr, CRP 120 mg/L. Blood cultures: MRSA in 2/2 sets. MRI lumbar spine with contrast: dorsal epidural collection L2-L4 with significant canal compromise and enhancement consistent with epidural abscess, plus adjacent vertebral osteomyelitis; no discrete psoas abscess. He is started on IV vancomycin. Neurosurgery feels surgery is high risk due to severe cardiomyopathy (EF 20%) and active drug use, recommending medical therapy unless deterioration. What is the most appropriate next step?", "options": ["Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks", "Add rifampin to vancomycin to enhance penetration into epidural space and bone", "Perform urgent surgical decompression and drainage despite high perioperative risk", "Switch to daptomycin plus ceftaroline to provide broader MRSA coverage", "Place percutaneous CT-guided drain into the epidural collection to avoid open surgery"], "answer": "C", "answer_index": 2, "explanation": "He has spinal epidural abscess with evolving motor deficit and significant canal compromise; urgent surgical decompression and drainage is indicated despite elevated operative risk, as delay risks permanent paralysis. Medical therapy alone (A, B, D) is inadequate once neurologic deficits are present. Percutaneous drainage (E) is not appropriate for epidural abscess causing cord compression, as it rarely achieves effective decompression or safe access to the epidural space.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "topics_mapped", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "source_question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T045001943Z_gpt-5.1-2025-11-13_seed124.jsonl", "pred": "E", "model_outputs": "The patient has a spinal epidural abscess with neurologic deficit (right leg weakness 3/5) and significant spinal canal compromise, which is a neurosurgical emergency.  \nAlthough neurosurgery initially recommended medical management due to high surgical risk, the presence of a progressive neurologic deficit is a strong indication for decompression.  \nPercutaneous CT-guided drainage (option E) can be an alternative to open surgery in selected cases and may reduce the mass effect while avoiding high-risk open surgery.  \nGiven the high operative risk from severe cardiomyopathy, a less invasive drainage procedure is appropriate before considering open surgery.  \n\nThe answer is E"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-009", "question": "A 54-year-old man with metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) previously treated with platinum-doublet chemotherapy plus pembrolizumab achieves a partial response for 10 months and then develops radiographic progression in lung and liver. Next-generation sequencing on a liver biopsy shows persistent KRAS G12C, a new MET amplification (copy number 9), and no other targetable alterations. PD-L1 TPS is 80%. He is ECOG 1 with adequate organ function. Which of the following is the most appropriate next-line systemic therapy strategy?\n\nA. Switch to docetaxel and ramucirumab\nB. Start adagrasib monotherapy targeting KRAS G12C\nC. Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination\nD. Restart pembrolizumab monotherapy at an increased dose\nE. Use carboplatin, paclitaxel, and bevacizumab re-induction", "options": ["Switch to docetaxel and ramucirumab", "Start adagrasib monotherapy targeting KRAS G12C", "Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination", "Restart pembrolizumab monotherapy at an increased dose", "Use carboplatin, paclitaxel, and bevacizumab re-induction"], "answer": "C", "answer_index": 2, "explanation": "Emergent MET amplification is a known resistance mechanism to KRAS G12C inhibitors, and early data suggest combined KRAS G12C plus MET blockade may overcome resistance, making a combination clinical trial the most rational choice. Adagrasib monotherapy (B) will likely be undermined by the MET-driven bypass track. Docetaxel/ramucirumab (A) is standard chemo after immunotherapy but ignores a newly actionable resistance pathway in a trial-eligible patient. Pembrolizumab dose escalation (D) and re-induction platinum doublet with bevacizumab (E) are unlikely to benefit after clear progression on prior chemoimmunotherapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed131.jsonl", "pred": "C", "model_outputs": "The patient has progressed on first-line platinum-doublet chemotherapy plus pembrolizumab and now has two targetable alterations: persistent KRAS G12C and a newly acquired MET amplification. While KRAS G12C inhibitors like adagrasib are approved in this setting, MET amplification is a known resistance mechanism to such inhibitors, making monotherapy suboptimal. A clinical trial combining a KRAS G12C inhibitor with a MET inhibitor would address both alterations and is the most rational strategy.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_gpt-5.1-2025-11-13_p03", "question_id": "ABMS20260101_gpt-5.1-2025-11-13_p03-010", "question": "A 37-year-old woman develops generalized urticaria, throat tightness, and hypotension within 10 minutes of receiving a first infusion of rituximab for relapsed follicular lymphoma. Symptoms resolve completely with epinephrine, antihistamines, and steroids; tryptase 90 minutes after onset is elevated. Skin testing later shows strong positive intradermal response to rituximab at non-irritating concentrations. She requires anti-CD20 therapy for disease control and has failed obinutuzumab. Which is the most appropriate management of her need for B-cell-depleting therapy?\n\nA. Avoid all monoclonal antibodies and use lenalidomide alone\nB. Perform rapid drug desensitization to rituximab under intensive monitoring\nC. Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization\nD. Switch to ofatumumab without further allergy evaluation\nE. Use omalizumab for 3 months before rechallenging with rituximab at full dose", "options": ["Avoid all monoclonal antibodies and use lenalidomide alone", "Perform rapid drug desensitization to rituximab under intensive monitoring", "Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization", "Switch to ofatumumab without further allergy evaluation", "Use omalizumab for 3 months before rechallenging with rituximab at full dose"], "answer": "B", "answer_index": 1, "explanation": "Positive skin testing and elevated tryptase confirm IgE-mediated anaphylaxis to rituximab; the standard of care when the culprit agent is uniquely needed is a rapid desensitization protocol in a specialized setting. Premedication and slow infusion without desensitization (C) is unsafe in IgE-mediated reactions. Cross-reactivity among anti-CD20 mAbs is unpredictable, so empiric switch to ofatumumab (D) risks repeat anaphylaxis. Omalizumab pretreatment (E) is not a substitute for true desensitization. Completely abandoning monoclonals (A) compromises optimal lymphoma care without necessity.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy/Immunology", "source_quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "source_question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gpt-5.1-2025-11-13/20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T225810101Z_gpt-5.1-2025-11-13_seed131.jsonl", "pred": "B", "model_outputs": "The patient had a severe immediate hypersensitivity reaction to rituximab with elevated tryptase and positive skin testing, confirming an IgE-mediated or other immune-mediated mechanism.  \nShe needs anti-CD20 therapy and failed obinutuzumab.  \nRapid drug desensitization is a standard approach for patients with confirmed hypersensitivity to a first-line medication when alternatives are limited, allowing temporary tolerance during infusion.  \nPremedication alone (C) is insufficient given the severity and confirmed allergy. Switching to another anti-CD20 without evaluation (D) risks cross-reactivity. Omalizumab (E) is not standard for pre-treatment in this scenario. Avoiding all monoclonal antibodies (A) is unnecessary when desensitization is possible.  \n\nThe answer is (B)"}]